Cancer drug developer Dendreon announced Q4 revenue early. And revenue was good.
Gross product revenue jumped 230% year-over-year to $82 million. This also represents a 25% increase from Q3.
“We are pleased with the progress we have made in the launch of PROVENGE, which — based on its first full year of revenues — places it as one of the top 10 product launches in oncology,” said CEO Mitchell Gold, MD.
The stock is up nearly 40% this morning.
This according to CNBC. More details to follow as the story develops.